SHENYANG, China, Feb. 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that Mr. Mingde Yu has been appointed as an independent director of the Company. Mr. Yu succeeds Mr. Guanjin Hu, a director of 3SBio since August 2006, who has tendered his resignation as a result of his increasing official work commitments. The appointment of Mr. Yu took effect on February 15, the effective date of Mr. Hu's resignation.
Dan Lou, Chairman of 3SBio, commented, "On behalf of the Board, I would like to welcome Mingde Yu to 3SBio. Mr. Yu brings to 3SBio a wealth of knowledge and experience gained over a long and distinguished career in the pharmaceutical industry in China. He will be a vital resource to the Board as we continue to grow the business and create shareholder value. I would also like to thank Mr. Guanjin Hu for his contributions to the Company's success, and wish him all the best in his future endeavors."
Mr. Yu, 62, has extensive experience in manufacturing and distribution
management in the pharmaceutical industry in China. He has held a number of
senior positions both in the government and the private sectors, including
as the Chief Technology Officer and the Head of Manufacturing at both
Liaoning Fuxi Pharmaceutical Co. and Fuxi Traditional Chinese Medicine Co.,
Bureau Chief of the Fuxi City Food & Drug Administration, Bureau Chief of
the Liaoning Provincial Food & Drug Administration, Drug Department Chief
of the Economic Operations Bureau of the State Economic and Trade
Committee, and Vice-Bureau Chief of Economic Operations Department
|SOURCE 3SBio Inc.|
Copyright©2008 PR Newswire.
All rights reserved